CN110520152A - 与靶向组织因子的igg3免疫缀合物有关的方法和组合物 - Google Patents

与靶向组织因子的igg3免疫缀合物有关的方法和组合物 Download PDF

Info

Publication number
CN110520152A
CN110520152A CN201880018514.6A CN201880018514A CN110520152A CN 110520152 A CN110520152 A CN 110520152A CN 201880018514 A CN201880018514 A CN 201880018514A CN 110520152 A CN110520152 A CN 110520152A
Authority
CN
China
Prior art keywords
leu
ser
val
glu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880018514.6A
Other languages
English (en)
Chinese (zh)
Inventor
胡志伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio Innovation Foundation
Original Assignee
Ohio Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio Innovation Foundation filed Critical Ohio Innovation Foundation
Publication of CN110520152A publication Critical patent/CN110520152A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880018514.6A 2017-03-14 2018-03-14 与靶向组织因子的igg3免疫缀合物有关的方法和组合物 Pending CN110520152A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762471045P 2017-03-14 2017-03-14
US62/471,045 2017-03-14
US201762576278P 2017-10-24 2017-10-24
US62/576,278 2017-10-24
US201862623269P 2018-01-29 2018-01-29
US62/623,269 2018-01-29
PCT/US2018/022443 WO2018170134A1 (en) 2017-03-14 2018-03-14 Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates

Publications (1)

Publication Number Publication Date
CN110520152A true CN110520152A (zh) 2019-11-29

Family

ID=63523847

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880018514.6A Pending CN110520152A (zh) 2017-03-14 2018-03-14 与靶向组织因子的igg3免疫缀合物有关的方法和组合物

Country Status (8)

Country Link
US (2) US11872194B2 (https=)
EP (1) EP3595707A4 (https=)
JP (1) JP7155144B2 (https=)
CN (1) CN110520152A (https=)
AU (1) AU2018235945A1 (https=)
CA (1) CA3056396A1 (https=)
MA (1) MA47786A (https=)
WO (1) WO2018170134A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3687555A4 (en) * 2017-09-27 2021-07-21 Ohio State Innovation Foundation CAR-NK CELL THERAPY AND CAR-T TISSUE FACTOR TARGETING
WO2022106648A1 (en) 2020-11-20 2022-05-27 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Inhibitors of the tissue factor-protease activated receptor 2 (tf-par2) signaling pathway for use in the treatment or prevention of heart failure (hf) and associated or resulting diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101740A2 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US20050214298A1 (en) * 1999-07-01 2005-09-29 Yale University Neovascular-targeted immunoconjugates
US20060024730A1 (en) * 2002-07-12 2006-02-02 Novo Nordisk A/S TF binding compounds
CN103180439A (zh) * 2010-07-09 2013-06-26 比奥根艾迪克依蒙菲利亚公司 嵌合凝血因子
CN103397009A (zh) * 2013-08-16 2013-11-20 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5079262A (en) 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US5166197A (en) 1990-07-17 1992-11-24 Kenney Malcolm E Phthalocyanine photosensitizers for photodynamic therapy
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
DK1198479T3 (da) 1999-07-01 2008-10-13 Univ Yale Neovaskulamålrettet immunkonjugat
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
CA2408323C (en) 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
BR112018001148A2 (pt) * 2015-08-06 2018-09-11 Glycotope Gmbh heterômeros compreendendo proteínas de fusão com domínios de anticorpos
EP3442554A4 (en) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214298A1 (en) * 1999-07-01 2005-09-29 Yale University Neovascular-targeted immunoconjugates
US20060024730A1 (en) * 2002-07-12 2006-02-02 Novo Nordisk A/S TF binding compounds
WO2004101740A2 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Clotting factor-fc chimeric proteins to treat hemophilia
CN103180439A (zh) * 2010-07-09 2013-06-26 比奥根艾迪克依蒙菲利亚公司 嵌合凝血因子
CN103397009A (zh) * 2013-08-16 2013-11-20 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABHISHEK SAXENA等: "Advances in therapeutic Fc engineering–modulation of IgG-associated effector functions and serum half-life", vol. 7, pages 580 *
HYE IN PARK等: "The highly evolvable antibody Fc Domain", vol. 34, no. 11, pages 895 - 908, XP029778354, DOI: 10.1016/j.tibtech.2016.04.005 *
ZHIWEI HU等: "Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 3, no. 2, pages 304 *

Also Published As

Publication number Publication date
AU2018235945A1 (en) 2019-10-17
JP2020511140A (ja) 2020-04-16
US20200085922A1 (en) 2020-03-19
JP7155144B2 (ja) 2022-10-18
MA47786A (fr) 2020-01-22
EP3595707A1 (en) 2020-01-22
US11872194B2 (en) 2024-01-16
WO2018170134A1 (en) 2018-09-20
EP3595707A4 (en) 2021-01-13
CA3056396A1 (en) 2018-09-20
US20240123042A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
US12195519B2 (en) Transforming growth factor-beta (TGF-beta) receptor type II fusion polypeptides
KR102603899B1 (ko) 골수형성이상 증후군 및 철적혈모구 빈혈을 치료하기 위한 방법
AU2021201185A1 (en) Methods and compositions for treating ulcers
RU2559532C2 (ru) Антагонисты рецептора и лигандов alk1 и их применение
DK1928910T3 (en) A method for mass production of an immunoglobulin Fc region without the initiating methionine residues
KR102461210B1 (ko) Uti 융합 단백질
US20220089683A1 (en) Bi-and tri-functional fusion proteins and uses thereof
KR20140123558A (ko) Alk1 길항제 및 신세포 암종 치료에서의 그의 용도
US20240123042A1 (en) Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates
US12103959B2 (en) Multispecific binders of TGFBeta-superfamily ligands and uses thereof
KR102711074B1 (ko) 암 생존자 유래 항체 및 이의 용도
US20230398181A1 (en) Treatments for complications associated with chronic liver disease
KR20210087016A (ko) 양기능 혈관신생 억제제 및 그의 용도
US20230398182A1 (en) Treatments for hermansky-pudlak syndrome
CN114401995B (zh) TGF-β陷阱
KR101153393B1 (ko) 점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
HK40073489A (en) Tgf-beta trap
BR122024022051A2 (pt) POLINUCLEOTÍDEO COMPREENDENDO UMA SEQUÊNCIA DE CODIFICAÇÃO DE UM POLIPEPTÍDEO DE FUSÃO DO RECEPTOR DO FATOR DE TRANSFORMAÇÃO DO CRESCIMENTO betaII (TbetaRII), POLINUCLEOTÍDEO RECOMBINANTE, CÉLULA, MÉTODO PARA PRODUZIR UM POLIPEPTÍDEO DE FUSÃO DO TbetaRII, BEM COMO DITO POLIPEPTÍDEO DE FUSÃO DO TbetaRII

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191129